27479458|t|Effects of Montelukast in an Experimental Model of Acute Pancreatitis
27479458|a|BACKGROUND We evaluated the hematological, biochemical, and histopathological effects of Montelukast on pancreatic damage in an experimental acute pancreatitis model created by cerulein in rats before and after the induction of pancreatitis. MATERIAL AND METHODS Forty rats were divided into 4 groups with 10 rats each. The study groups were: the Cerulein (C) group, the Cerulein + early Montelukast (CMe) group, the Cerulein + late Montelukast (CMl) group, and the Control group. The pH, pO2, pCO2, HCO3, leukocyte, hematocrit, pancreatic amylase, and lipase values were measured in the arterial blood samples taken immediately before rats were killed. RESULTS There were statistically significant differences between the C group and the Control group in the values of pancreatic amylase, lipase, blood leukocyte, hematocrit, pH, pO2, pCO2, HCO3, and pancreatic water content, and also in each of the values of edema, inflammation, vacuolization, necrosis, and total histopathological score (P<0.05). When the CMl group and C group were compared, no statistically significant differences were found in any parameter analyzed. When the CMe group was compared with the C group, pancreatic amylase, lipase, pH, PO2, pCO2, HCO3, pancreatic water content, histopathological edema, inflammation, and total histopathological score values were significantly different between the groups (P<0.05). Finally, when the CMe group and the Control group were compared, significant differences were found in all except 2 (leukocyte and pO2) parameters (P<0.05). CONCLUSIONS Leukotriene receptor antagonists used in the late phases of pancreatitis might not result in any benefit; however, when they are given in the early phases or prophylactically, they may decrease pancreatic damage.
27479458	11	22	Montelukast	T103	UMLS:C0298130
27479458	29	47	Experimental Model	T170	UMLS:C0086272
27479458	51	69	Acute Pancreatitis	T038	UMLS:C0001339
27479458	84	93	evaluated	T058	UMLS:C0220825
27479458	159	170	Montelukast	T103	UMLS:C0298130
27479458	174	184	pancreatic	T017	UMLS:C0030274
27479458	211	229	acute pancreatitis	T038	UMLS:C0001339
27479458	230	235	model	T038	UMLS:C0684309
27479458	247	255	cerulein	T103	UMLS:C0006639
27479458	259	263	rats	T204	UMLS:C0034693
27479458	298	310	pancreatitis	T038	UMLS:C0030305
27479458	339	343	rats	T204	UMLS:C0034693
27479458	364	370	groups	T098	UMLS:C1257890
27479458	379	383	rats	T204	UMLS:C0034693
27479458	394	406	study groups	T098	UMLS:C2348561
27479458	417	425	Cerulein	T103	UMLS:C0006639
27479458	427	428	C	T103	UMLS:C0006639
27479458	430	435	group	T098	UMLS:C1257890
27479458	441	449	Cerulein	T103	UMLS:C0006639
27479458	458	469	Montelukast	T103	UMLS:C0298130
27479458	476	481	group	T098	UMLS:C1257890
27479458	487	495	Cerulein	T103	UMLS:C0006639
27479458	503	514	Montelukast	T103	UMLS:C0298130
27479458	521	526	group	T098	UMLS:C1257890
27479458	559	562	pO2	T038	UMLS:C0391840
27479458	564	568	pCO2	T033	UMLS:C0391839
27479458	570	574	HCO3	T103	UMLS:C0005367
27479458	576	585	leukocyte	T017	UMLS:C0023516
27479458	587	597	hematocrit	T033	UMLS:C0518014
27479458	599	617	pancreatic amylase	T103	UMLS:C0301812
27479458	623	629	lipase	T103	UMLS:C0023764
27479458	658	680	arterial blood samples	T031	UMLS:C0444253
27479458	706	710	rats	T204	UMLS:C0034693
27479458	793	794	C	T103	UMLS:C0006639
27479458	795	800	group	T098	UMLS:C1257890
27479458	840	858	pancreatic amylase	T103	UMLS:C0301812
27479458	860	866	lipase	T103	UMLS:C0023764
27479458	868	883	blood leukocyte	T017	UMLS:C0023516
27479458	885	895	hematocrit	T033	UMLS:C0518014
27479458	901	904	pO2	T038	UMLS:C0391840
27479458	906	910	pCO2	T033	UMLS:C0391839
27479458	912	916	HCO3	T103	UMLS:C0005367
27479458	922	932	pancreatic	T017	UMLS:C0030274
27479458	982	987	edema	T033	UMLS:C0013604
27479458	989	1001	inflammation	T038	UMLS:C0021368
27479458	1003	1016	vacuolization	T033	UMLS:C0010840
27479458	1018	1026	necrosis	T038	UMLS:C0027540
27479458	1085	1090	group	T098	UMLS:C1257890
27479458	1095	1096	C	T103	UMLS:C0006639
27479458	1097	1102	group	T098	UMLS:C1257890
27479458	1177	1186	parameter	T033	UMLS:C0449381
27479458	1210	1215	group	T098	UMLS:C1257890
27479458	1238	1239	C	T103	UMLS:C0006639
27479458	1240	1245	group	T098	UMLS:C1257890
27479458	1247	1265	pancreatic amylase	T103	UMLS:C0301812
27479458	1267	1273	lipase	T103	UMLS:C0023764
27479458	1279	1282	PO2	T038	UMLS:C0391840
27479458	1284	1288	pCO2	T033	UMLS:C0391839
27479458	1290	1294	HCO3	T103	UMLS:C0005367
27479458	1296	1306	pancreatic	T017	UMLS:C0030274
27479458	1340	1345	edema	T033	UMLS:C0013604
27479458	1347	1359	inflammation	T038	UMLS:C0021368
27479458	1443	1449	groups	T098	UMLS:C1257890
27479458	1482	1487	group	T098	UMLS:C1257890
27479458	1577	1586	leukocyte	T017	UMLS:C0023516
27479458	1591	1594	pO2	T038	UMLS:C0391840
27479458	1596	1606	parameters	T033	UMLS:C0449381
27479458	1629	1661	Leukotriene receptor antagonists	T103	UMLS:C0595726
27479458	1689	1701	pancreatitis	T038	UMLS:C0030305
27479458	1823	1833	pancreatic	T017	UMLS:C0030274